已接种和未接种人乳头瘤病毒疫苗女性宫颈上皮内瘤变2级进展风险:一项基于人群的队列研究
丹麦基于全国健康登记数据的队列研究纳入7904例18-40岁宫颈上皮内瘤变2级(CIN2)主动监测女性,其中3867例(48.9%)在CIN2诊断前至少1年接种过HPV疫苗。28个月随访期内,15岁前接种者进展为CIN3+的累积风险为22.9%,15-20岁接种者为31.5%,均低于未接种者的37.6%;调整后相对风险分别为0.65和0.86,而20岁后接种者与未接种者相当(aRR 1.02)。
要点
- 15岁前接种HPV疫苗者28个月CIN3+累积风险22.9%,低于未接种者的37.6%。
- 15-20岁接种者累积风险31.5%,调整后相对风险0.86,仍低于未接种者。
- 20岁后接种者进展风险与未接种者相当,调整后相对风险1.02。
核心结论
- 在28个月随访期间,CIN2主动监测女性中接种HPV疫苗者进展为CIN3+的风险低于未接种者,但仅限于20岁前接种疫苗者。
- 作者认为这些发现可能提示HPV疫苗接种状态可用于CIN2临床管理中的风险分层。
研究设计与样本
- 基于丹麦全国健康登记数据的基于人群的队列研究,纳入2007年1月1日至2020年12月31日期间18-40岁接受CIN2主动监测的女性。
- 排除既往有CIN2或更严重病变、子宫切除或宫颈环形电切术记录者。
- 暴露定义为CIN2诊断前至少1年接种过至少1剂HPV疫苗;研究人群共7904例,其中3867例(48.9%)为接种者。
- 采用累积发生率函数估计28个月内进展为CIN3+的风险,以子宫切除、移民和死亡为竞争事件;采用改良Poisson回归计算粗相对风险和调整相对风险。
- 结果按接种年龄分层,并调整指标细胞学、可支配收入和受教育程度。
主要发现
- CIN2诊断时,接种者中位年龄25岁(四分位距23-27岁),未接种者中位年龄29岁(四分位距25-33岁)。
- 28个月CIN3+累积风险:15岁前接种者为22.9%(95%CI 19.8-26.1),15-20岁接种者为31.5%(95%CI 28.8-34.3),未接种者为37.6%(95%CI 36.1-39.1)。
- 与未接种者相比,15岁前接种者进展为CIN3+的调整相对风险为0.65(95%CI 0.57-0.75),相当于风险降低35%。
- 与未接种者相比,15-20岁接种者进展为CIN3+的调整相对风险为0.86(95%CI 0.79-0.95),相当于风险降低14%。
- 20岁后接种者与未接种者进展风险相当,调整相对风险为1.02(95%CI 0.96-1.09)。
临床怎么用
- 作者认为HPV疫苗接种状态可能用于CIN2临床管理中的风险分层。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Many countries have implemented active surveillance (ie, leaving the lesion untreated) as an option among younger women with cervical intraepithelial neoplasia grade 2 because regression rates are high and excisional treatment increases the risk for preterm birth in subsequent pregnancies. However, early identification of women at increased risk for progression to cervical intraepithelial neoplasia grade 3 or worse is important to ensure timely treatment. Because women who have received a human papillomavirus vaccine have a lower risk for cervical cancer, they may have a lower risk for progression of untreated cervical intraepithelial neoplasia grade 2 to cervical intraepithelial neoplasia grade 3 or worse. OBJECTIVE: This study aimed to investigate if women who received a human papillomavirus vaccine and who are undergoing active surveillance for cervical intraepithelial neoplasia grade 2 are less likely to progress to cervical intraepithelial neoplasia grade 3 or worse when compared with women who did not receive the vaccine. STUDY DESIGN: We conducted a population-based cohort study in Denmark using data from national health registers. We identified all women aged 18 to 40 years who were undergoing active surveillance for cervical intraepithelial neoplasia grade 2 from January 1, 2007, to December 31, 2020. Women with a previous record of cervical intraepithelial neoplasia grade 2 or worse, hysterectomy, or a loop electrosurgical excision procedure were excluded. Exposure was defined as having received ≥1 dose of a human papillomavirus vaccine at least 1 year before the cervical intraepithelial neoplasia grade 2 diagnosis. We used cumulative incidence functions to estimate the risk for progression to cervical intraepithelial neoplasia grade 3 or worse within 28 months using hysterectomy, emigration, and death as competing events. We used modified Poisson regression to calculate crude and adjusted relative risks of progression during the 28-month surveillance period. Results were stratified by age at vaccination and adjusted for index cytology, disposable income, and educational level. RESULTS: The study population consisted of 7904 women of whom 3867 (48.9%) were vaccinated at least 1 year before a diagnosis of cervical intraepithelial neoplasia grade 2. At the time of cervical intraepithelial neoplasia grade 2 diagnosis, women who were vaccinated were younger (median age, 25 years; interquartile range, 23-27 years) than those who were not (median age, 29 years; interquartile range, 25-33 years). The 28-month cumulative risk for cervical intraepithelial neoplasia grade 3 or worse was significantly lower among women who were vaccinated before the age of 15 years (22.9%; 95% confidence interval, 19.8-26.1) and between the ages of 15 and 20 years (31.5%; 95% confidence interval, 28.8-34.3) when compared with women who were not vaccinated (37.6%; 95% confidence interval, 36.1-39.1). Thus, when compared with women who were not vaccinated, those who were vaccinated before the age of 15 years had a 35% lower risk for progression to cervical intraepithelial neoplasia grade 3 or worse (adjusted relative risk, 0.65; 95% confidence interval, 0.57-0.75), whereas women who were vaccinated between the ages of 15 and 20 years had a 14% lower risk (adjusted relative risk, 0.86; 95% confidence interval, 0.79-0.95). For women who were vaccinated after the age of 20 years, the risk was comparable with that among women who were not vaccinated (adjusted relative risk, 1.02; 95% confidence interval, 0.96-1.09). CONCLUSION: Women who were vaccinated and who were undergoing active surveillance for cervical intraepithelial neoplasia grade 2 had a lower risk for progression to cervical intraepithelial neoplasia grade 3 or worse during 28 months of follow-up when compared with women who were not vaccinated but only if the vaccine was administered by the age of 20 years. These findings may suggest that the human papillomavirus vaccination status can be used for risk stratification in clinical management of cervical intraepithelial neoplasia grade 2.
引用
- Krog L, Lycke KD, Kahlert J, et al. Risk of progression of cervical intraepithelial neoplasia grade 2 in human papillomavirus-vaccinated and unvaccinated women: a population-based cohort study. Am J Obstet Gynecol. 2023. PMID: 38569830. doi:10.1016/j.ajog.2023.11.1235
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。